Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × NSCLC × Pharmaceutical Preparations × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Neoplasms, Plasma Cell 1 NSCLC 1 Multiple Myeloma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

osimertinib 2 aflutinib 2 rezivertinib 1 pembrolizumab 1 lenvatinib 1 brigatinib 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiotherapy 1 Pharmaceutical Preparations 1 JDQ443 1 Gefitinib 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡